The effect of Palmitoylethanolamide on the treatment of negative symptoms in patients with chronic schizophrenia
Phase 2
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT20090117001556N127
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Age between 18 to 60 years
Take Risperidone for at least 4 weeks at the dose of 4-6 mg/day before entering the study
The positive and acute symptoms of patients should be stable
Exclusion Criteria
Head trauma
History of shock therapy during past three months prior to the trial
Undergoing neurosurgery
Presence of acute or chronic systemic diseases
History of allergy to Cilostazol
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of schizophrenia. Timepoint: Baseline and weeks 4 and 8. Method of measurement: By Positive and Negative Syndrome Scale (PANSS).
- Secondary Outcome Measures
Name Time Method